Project description DEENESFRITPL Tailored nanomedicines for breast cancer There is often variability in treatment outcome in cancer patients. This stems from differences in the underlying biology of the cancer, as well as differences in the patient’s overall health, genetics and lifestyle. Therefore, there is a need to tailor treatment regimens to individual patients based on their unique characteristics. The EU-funded MyNano project aims to engineer personalised polymer-based combination therapies for breast cancer patients. Researchers will optimise the design of nanoconjugates for specific clinical subtypes, introducing a paradigm shift in the design of nanomedicines for areas of unmet clinical need. The use of polymer conjugates in drug design can improve therapeutic efficiency and reduce related toxicity. Show the project objective Hide the project objective Objective Research on anticancer therapies has provided little progress towards improved survival rates for patients with metastatic disease. The intrinsic advantages of polymer conjugates can be optimised to rationally design targeted combination therapies, concept I pioneered that allows enhanced therapeutic efficiency. Early clinical trials involving conjugates showed activity in chemotherapy refractory patients and reduced drug-related toxicity. However, there is a growing concern on patient variability regarding tumor patho-physiology that underlie successful therapeutic outcome. Specific biomarkers are required to select those patients most likely to show good clinical response to these therapies. The objective of MyNano is to engineer polymer-based combination therapies designed to treat metastatic breast cancer in a patient personalised manner. Therefore, novel multicomponent polymer conjugates with precise control over size, shape, solution conformation, multifunctionality and bioresponsiveness will be obtained while in parallel their structure activity relationships to underlying proposed mechanisms of action in clinically relevant models will be studied. Polyglutamates obtained by controlled polymerisation and self-assembly strategies will be the carriers. Primary breast cancer patient tissue will be used to generate cell and in vivo models representing different clinical molecular subtypes. MyNano will also investigate new combination strategies using current treatments together with inhibitors of tumor-derived exosome release pathways, phenomenon related to metastasis and resistance mechanisms. The aim is to provide a novel methodological approach that would allow by reiterative design to optimise the design of the next generation nanoconjugates for the treatment of specific metastatic cancer clinical subtypes. MyNano will be a breakthrough as it introduces a paradigm shift in the strategy to design nanomedicines in areas of unmet clinical need. Fields of science medical and health sciencesbasic medicinephysiologypathophysiologynatural sciencesbiological sciencescell biologynatural scienceschemical sciencespolymer sciencesmedical and health sciencesmedical biotechnologynanomedicinemedical and health sciencesclinical medicineoncologybreast cancer Programme(s) H2020-EU.1.1. - EXCELLENT SCIENCE - European Research Council (ERC) Main Programme Topic(s) ERC-CoG-2014 - ERC Consolidator Grant Call for proposal ERC-2014-CoG See other projects for this call Funding Scheme ERC-COG - Consolidator Grant Host institution FUNDACION DE LA COMUNIDAD VALENCIANA CENTRO DE INVESTIGACION PRINCIPEFELIPE Net EU contribution € 1 724 168,97 Address CALLE EDUARDO PRIMO YUFERA 3 46012 Valencia Spain See on map Region Este Comunitat Valenciana Valencia/València Activity type Research Organisations Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 1 724 168,97 Beneficiaries (1) Sort alphabetically Sort by Net EU contribution Expand all Collapse all FUNDACION DE LA COMUNIDAD VALENCIANA CENTRO DE INVESTIGACION PRINCIPEFELIPE Spain Net EU contribution € 1 724 168,97 Address CALLE EDUARDO PRIMO YUFERA 3 46012 Valencia See on map Region Este Comunitat Valenciana Valencia/València Activity type Research Organisations Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 1 724 168,97